Skip to main content

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.

Journal articles  - Journal Article
Thatte, J; Moisés da Silva, A; Börcsök, J; Gudjónsson, T; Benada, J; Li, X; Bose, M; van der Gulden, H; Song, J-Y; Menezes, R; Martín-Doncel, E ...
Published in: The Journal of clinical investigation
June 2025

Loss-of-function mutations in genome maintenance genes fuel tumorigenesis through increased genomic instability. A subset of these tumor suppressors are challenging to identify due to context dependency, including functional interactions with other genes and pathways. Here, we searched for potential causal genes that impact tumor development and/or progression in breast cancer through functional-genetic screening of candidate genes. MYH4, encoding a class II myosin, emerged as a top hit impacting genomic stability. We show that MYH4 suppresses DNA replication stress by promoting replication licensing and replication fork progression. Moreover, we observed a strong synergistic relationship among class II myosins in suppressing replication-associated DNA damage. Genomic analysis of Pan-Cancer Analysis of Whole Genomes project breast cancer samples revealed frequent concomitant loss of TP53 with MYH4 and class II myosins on chromosome 17p. Notably, Myh4 disruption accelerated mouse mammary tumorigenesis in a Trp53-deficient background. In conclusion, our results suggest an unanticipated function of MYH4 in p53-mediated tumor suppression that can explain their combined loss in breast cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The Journal of clinical investigation

DOI

EISSN

1558-8238

ISSN

0021-9738

Publication Date

June 2025

Volume

135

Issue

11

Start / End Page

e188165

Related Subject Headings

  • Tumor Suppressor Protein p53
  • Neoplasm Proteins
  • Myosin Heavy Chains
  • Mice, Knockout
  • Mice
  • Immunology
  • Humans
  • Genomic Instability
  • Female
  • DNA Replication
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thatte, J., Moisés da Silva, A., Börcsök, J., Gudjónsson, T., Benada, J., Li, X., … Sørensen, C. S. (2025). The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression. The Journal of Clinical Investigation, 135(11), e188165. https://doi.org/10.1172/jci188165
Thatte, Jayashree, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, et al. “The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.” The Journal of Clinical Investigation 135, no. 11 (June 2025): e188165. https://doi.org/10.1172/jci188165.
Thatte J, Moisés da Silva A, Börcsök J, Gudjónsson T, Benada J, Li X, et al. The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression. The Journal of clinical investigation. 2025 Jun;135(11):e188165.
Thatte, Jayashree, et al. “The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.” The Journal of Clinical Investigation, vol. 135, no. 11, June 2025, p. e188165. Epmc, doi:10.1172/jci188165.
Thatte J, Moisés da Silva A, Börcsök J, Gudjónsson T, Benada J, Li X, Bose M, van der Gulden H, Song J-Y, Menezes R, Martín-Doncel E, Toledo L, Petrosius V, Brakebusch C, Jonkers J, Nielsen FC, Rossing M, Sørensen CS. The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression. The Journal of clinical investigation. 2025 Jun;135(11):e188165.

Published In

The Journal of clinical investigation

DOI

EISSN

1558-8238

ISSN

0021-9738

Publication Date

June 2025

Volume

135

Issue

11

Start / End Page

e188165

Related Subject Headings

  • Tumor Suppressor Protein p53
  • Neoplasm Proteins
  • Myosin Heavy Chains
  • Mice, Knockout
  • Mice
  • Immunology
  • Humans
  • Genomic Instability
  • Female
  • DNA Replication